Skip to content
DataLookout
Menu

HYIMPACTNCT06938516

Prospective Observational Study On The Impact Of Nebilet In Blood Pressure Control In Hypertensive Patients (HYIMPACT)

StatusActive, Not Recruiting
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

Version history last read from ClinicalTrials.gov on Aug 29, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.

All 1 version: 1 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Enrollment closed, study ongoing
    • Trial sites expanded: 49 → 52 locations
    • Study completion pushed from Mar 2029 to Jun 2029
  2. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

Change in mean sitting systolic blood pressure from baseline to one year of treatment in hypertensive patients on Nebilet based treatment.
Timeframe: Baseline to 12 months

Secondary (10)

To assess the impact of Nebilet based treatment in changing diastolic BP (DBP) in hypertensive patients in real-world setting from baseline to one year of treatment.
Change in mean sitting SBP and DBP from baseline to two years and at the end of three years in hypertensive patients on Nebilet based treatment.
To evaluate the proportions of patients achieving target BP goal (<140/90 mm Hg) at different time points (12 months, 24 months, and 36 months of treatment) with Nebilet based as combination treatment.
To assess the association of various risk factors (diabetes, obesity, and hypercholesterolemia) on development of major cardiac events in patients who achieve BP control over a period of 36 months.
To study the prescription patterns of Nebilet®-based treatment in terms of frequency per day in real-world settings.
Show 5 moreShow less
To study the prescription patterns of Nebilet®-based treatment in terms of dose in milligrams in real-world settings.
To study the prescription patterns or Nebilet®-based treatment in terms of treatment duration in months, in real-world settings.
To assess the impact of Nebilet®-based treatment on the quality-of-life of patients using MINICHAL questionnaire.
To assess the patient-reported outcomes using a short form 36 health survey (SF-36 questionnaire) .
To assess patient adherence to treatment by an 8-item Morisky Medication Adherence Scale every 3 months after baseline, till 36 months.

Sites

52 sites in 7 countries

Indonesia 17, Taiwan 13, Thailand 6, Vietnam 6, Malaysia 5, South Korea 3, Philippines 2